title: [The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome].
abstract: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, oligo/anovulation and is associated with risk factors for cardiovascular diseases, such as insulin resistance and central adiposity. The aim of the study was to evaluation of influence of the oral contraceptive pill on the endocrinologic and metabolic parameters in women with PCOS.
  
  
  METHODS
  Forty nine PCOS women (aged 23,9 +/- 3,5 [mean +/- SD]) without any other diseases were included into the study. Oral contraceptives (0,02 mg ethynylestradiol + 0,15 mg desogestrel) were administered for 6 months. Hormonal and biochemical analyses were performed with specific assays at the beginning and after 6 month-therapy BMI, insulin sensitivity index (ISI) and QUICKI were calculated. Statistical analysis was performed using Wilcoxon test.
  
  
  RESULTS
  All patients completed 6-month therapy and no severe side effects were reported during the study. A significant reduction in testosterone (T) concentrations was observed (p<0.005). We recorded a significant increase in lipid concentrations.
  
  
  CONCLUSIONS
  The administration of oral contraceptives in our study group caused decrease in the testosterone level but negative effect on total cholesterol and triglycerides level was observed.
authors.affiliation: Klinika Niepłodności i Endokrynologii Rozrodu Katedry Ginekologii, Poloznictwa i Onkologii Ginekologicznej Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu. bbeata@gpsk.am.poznan.pl
authors.forename: Beata
authors.initials: B
authors.lastname: Banaszewska
authors.forename: Robert Z
authors.initials: RZ
authors.lastname: Spaczyński
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Ozegowska
authors.forename: Leszek
authors.initials: L
authors.lastname: Pawelczyk
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000378:metabolism; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage* / Q000009:adverse effects; D017135:Desogestrel / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000009:adverse effects*; D004997:Ethinyl Estradiol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D013739:Testosterone / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism; D055815:Young Adult
chemical_list: D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D014280:Triglycerides; D013739:Testosterone; D004997:Ethinyl Estradiol; D017135:Desogestrel; D002784:Cholesterol